These included well-known receptor tyrosine kinase genes (EGFR, TEK and OSMR) that activate MAPK and PI3K signaling pathways [40], and other tumor-promoter genes (ATP8B2, DAAM1, SLAMF8 and SRGN) [50,51,52,53] as well as tumor-suppressor genes (A2M, DAPK1, RASSF8 and SOCS3) [54,55,56,57]. The gene discussed is A2M; the disease is neoplasm.